
Ceribell Inc (CBLL) Stock Forecast & Price Target
Ceribell Inc (CBLL) Analyst Ratings
Bulls say
CeriBell Inc. is projecting a revenue increase to $87M-$89M in 2025, reflecting a year-over-year growth of 33%-36%, which indicates substantial commercial traction despite being in the early stages of its product rollout. The company is strategically investing in its salesforce and product pipeline, with plans to expand into new hospital markets and additional patient demographics, which underscores a long growth runway. Furthermore, with gross margins optimized in the mid-80% range, CeriBell is positioned to enhance profitability through operational leverage as it scales its operations.
Bears say
CeriBell Inc. is experiencing significant financial challenges, exemplified by a net loss of $40 million and a lack of positive free cash flow, which raises concerns about its sustainability in the medical technology sector. The company faces pressing margin headwinds due to increasing tariffs on imports from China and associated legal expenses, which could further degrade its gross margins and necessitate a shift in sourcing strategies. Additionally, the combination of geopolitical risks, supply chain vulnerabilities, and low market penetration heightens the overall risk profile of the company, contributing to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares